Dog Skin Cancer: Types, Warning Signs & Treatment Options

By Emiel Maddens  ·  Reviewed in consultation with licensed veterinary professionals  ·  Updated March 2026  ·  12 min read

Photo by Tima Miroshnichenko on Pexels

Skin cancer in dogs represents a significant clinical challenge in companion animal medicine. As dogs age, the incidence of cutaneous neoplasia increases substantially, with some surveys indicating that up to one-fifth of all tumors diagnosed in geriatric dogs are skin-related (Gross et al., 2005). Among these neoplasms, four malignancies account for the majority of cases: mast cell tumors (MCTs), melanomas, squamous cell carcinomas (SCCs), and hemangiosarcomas.

Early recognition of warning signs — including unusual growths, pigmented lesions, or non-healing wounds — provides opportunities for intervention before tumors progress to advanced stages. Understanding the distinguishing characteristics of each tumor type, the clinical signs that warrant veterinary evaluation, and the evidence-based treatment approaches available empowers dog owners to identify potential malignancies and make informed decisions regarding their dogs' care.

This comprehensive guide examines the epidemiology, clinical presentation, diagnostic evaluation, histologic grading, staging systems, and multimodal treatment options for the four most common canine skin cancers. Understanding these malignancies and their management is essential for both early detection and appropriate therapeutic selection.

Mast Cell Tumors: Characteristics, Grading, and Prognosis

Mast cell tumors are neoplasms derived from mast cells — tissue-resident cells of the innate immune system that produce and store biogenic amines including histamine and heparin. These amines mediate inflammatory and allergic responses. Mast cell tumors represent the most commonly diagnosed malignant skin tumor in dogs, accounting for approximately 15-25% of all skin tumors (Gross et al., 2005; Kiupel et al., 2011).

MCTs present with remarkable heterogeneity in biological behavior. Some MCTs remain localized and quiescent for extended periods, while others exhibit aggressive growth, early metastatic dissemination, and rapid progression to fatal systemic mastocytosis. This behavioral variability necessitates histologic evaluation to differentiate low-grade, intermediate-grade, and high-grade tumors — distinctions that profoundly influence prognosis and guide treatment decisions.

The Patnaik grading system, revised and refined in 2011 (Kiupel et al., 2011), categorizes MCTs into three grades based on cellular differentiation, mitotic activity, presence of multinucleated cells, and nuclear morphology. Grade I (well-differentiated) tumors exhibit a favorable prognosis with median survival times exceeding 4 years following appropriate local therapy. Grade II (intermediate-grade) tumors demonstrate intermediate biological behavior, with survival varying substantially based on additional clinical factors. Grade III (poorly differentiated) tumors are highly aggressive, frequently metastasize, and carry a guarded prognosis even with aggressive multimodal therapy.

Treatment of MCTs typically involves surgical excision of the primary tumor with wide margins (2-3 centimeter margins recommended). Many Grade II and Grade III tumors benefit from adjuvant chemotherapy — typically employing alkylating agents such as lomustine or tyrosine kinase inhibitors (toceranib phosphate) that target KIT mutations found in approximately 80% of canine MCTs. Radiation therapy may be employed when surgical margins cannot be adequately achieved. The presence of c-KIT mutations, assessed through molecular testing, provides prognostic information and guides selection of targeted tyrosine kinase inhibitor therapy.

Melanoma: Oral, Cutaneous, and Uveal Manifestations

Melanomas are malignancies derived from melanocytes — pigment-producing cells distributed throughout the skin and mucous membranes. These tumors represent the second most commonly diagnosed skin malignancy in dogs (Gross et al., 2005). Canine melanomas are characterized by aggressiveness and high metastatic potential, distinguishing them from their human counterparts which exhibit more variable behavior depending on molecular and histologic characteristics.

Oral melanomas are the most common intraoral tumor in dogs and carry a particularly guarded prognosis. These tumors develop within the gingiva (gums), hard palate, tongue, or lips and are often diagnosed only after substantial local tissue destruction has occurred. The oral cavity presents anatomical constraints that complicate surgical resection — margins must balance oncologic control against preservation of oral function and quality of life. Median survival times for oral melanoma with surgery alone range from 14-18 months, underscoring the aggressive nature of these tumors (Proulx et al., 2003).

Cutaneous melanomas develop within the skin and frequently occur on the digits (paws), mucocutaneous junctions, and non-haired skin. These tumors demonstrate lower metastatic potential than oral melanomas but still warrant aggressive management. The location of cutaneous melanomas influences prognosis, with digit melanomas carrying worse prognosis than tumors arising on non-haired skin. Amputation may be necessary for digit melanomas to achieve adequate surgical margins and reduce metastatic risk.

Uveal melanomas develop within the intraocular melanocytes of the ciliary body or iris and may affect vision. These tumors are frequently pigmented and visible on ophthalmic examination. While many uveal melanomas progress slowly, they can ultimately lead to vision loss if they enlarge and compromise the optic nerve or cause secondary glaucoma.

Treatment of melanoma is challenging and typically requires multimodal therapy. Surgical excision with wide margins (2-5 centimeters recommended) is the primary intervention, but combination chemotherapy (particularly platinum-based agents), immunotherapy, or radiation therapy may be employed in high-grade or metastatic cases to enhance survival times (Proulx et al., 2003). The aggressive biological behavior of canine melanomas means that prognosis remains guarded even with aggressive multimodal intervention.

Squamous Cell Carcinoma: Solar Exposure and Non-Healing Wounds

Squamous cell carcinomas are malignancies derived from keratinized stratified squamous epithelium — the outer cellular layer of the skin. These tumors represent the third most commonly diagnosed cutaneous malignancy in dogs (Gross et al., 2005). Unlike mast cell tumors and melanomas, squamous cell carcinomas tend to be more locally invasive initially, with metastatic spread to regional lymph nodes or distant organs occurring more commonly in advanced-stage disease.

Squamous cell carcinomas develop most frequently in areas of chronic sun exposure, particularly on sparsely haired or non-haired skin regions including the nose, ears, eyelids, and perineum. White-coated dogs and dogs with limited pigmentation are at substantially elevated risk due to reduced ultraviolet light protection from melanin. Chronic dermatological conditions including pemphigus vulgaris, chronic wounds, burn scars, or chronically inflamed skin can also predispose to SCC development independent of solar exposure.

Clinical presentation typically includes a non-healing ulcer, nodular growth, or erosive lesion that fails to respond to standard wound care or antimicrobial therapy. The lesion may progress over weeks to months, with destruction of surrounding tissues and formation of a crater-like ulceration. Histopathologic examination is essential for definitive diagnosis, as squamous cell carcinoma can be confused with other inflammatory or infectious conditions clinically.

Treatment of squamous cell carcinoma is primarily surgical, with wide margins (1-2 centimeters minimum) recommended to reduce local recurrence risk. Mohs micrographic surgery — a technique using intraoperative histologic assessment to ensure complete tumor removal while preserving normal tissue — is increasingly employed for SCCs in challenging anatomical locations (eyelids, nose) where margin control is difficult. For tumors that are not surgically resectable or demonstrate aggressive behavior, radiation therapy or chemotherapy may be employed as adjunctive or primary treatment modalities. Early detection and intervention substantially improve prognosis for canine squamous cell carcinoma.

Hemangiosarcoma: Aggressive Vascular Malignancy

Hemangiosarcomas are highly aggressive vascular malignancies derived from endothelial cells — the specialized cells lining blood vessels and lymphatic vessels. While hemangiosarcoma most commonly arises within abdominal organs (particularly the spleen) or the right atrial wall of the heart, approximately 5-7% of hemangiosarcomas occur as dermal or subcutaneous tumors (Gross et al., 2005). Cutaneous and subcutaneous hemangiosarcomas present unique diagnostic and prognostic challenges due to their vascular nature and aggressive behavior.

Cutaneous hemangiosarcomas typically present as rapidly enlarging, hairless, non-pigmented or reddish nodules with frequent ulceration and bleeding. The lesions may appear purplish or black due to hemorrhage within the tumor, and are often solitary. The rapid growth pattern and frequent bleeding should prompt urgent veterinary evaluation, as early diagnosis is critical. Many dogs with cutaneous hemangiosarcoma have concurrent visceral hemangiosarcoma, underscoring the systemic nature of this disease.

Early recognition of suspicious cutaneous lesions presents the opportunity for intervention before visceral dissemination occurs. Any hairless, rapidly enlarging nodule with spontaneous bleeding should be evaluated urgently. Histopathologic examination is essential for diagnosis, as the vascular nature of the lesion can be confused with other conditions on clinical presentation alone.

Treatment of cutaneous hemangiosarcoma involves wide surgical excision (2-3 centimeter margins recommended) combined with aggressive chemotherapy. Unlike cutaneous SCC or even melanoma, hemangiosarcoma's high propensity for systemic dissemination and vascular invasion makes multimodal therapy essential. Chemotherapy protocols employing doxorubicin or doxorubicin/cyclophosphamide combinations have demonstrated improved survival times compared to surgery alone. Nevertheless, prognosis remains guarded — median survival times with aggressive multimodal therapy approximate 12-18 months. Frequent staging (thoracic and abdominal imaging) is necessary to detect visceral metastases early.

Diagnostic Evaluation, Staging, and Histologic Grading

Definitive diagnosis of cutaneous malignancy requires histopathologic examination. Fine needle aspirate (FNA) — where cells are collected using a thin needle and examined microscopically — may provide preliminary information for some tumor types (particularly mast cell tumors), but excisional biopsy remains the gold standard. Excisional biopsy not only provides material for histopathologic diagnosis but also enables histologic assessment of margin status — whether the surgical specimen was entirely free of tumor cells.

Complete staging is essential for tumors with metastatic potential, including melanoma, hemangiosarcoma, and high-grade mast cell tumors. Staging typically includes thoracic radiography (chest X-rays) to evaluate for pulmonary metastases, abdominal ultrasound to evaluate regional lymph nodes and abdominal organs, and potentially CT imaging for complex cases. The TNM staging system — utilizing tumor size (T), lymph node involvement (N), and presence of distant metastases (M) — provides a standardized framework for categorizing tumors and predicting prognosis.

Histologic grading systems specific to each tumor type enable pathologists to quantify biological aggressiveness. Grading criteria typically assess cellular differentiation, mitotic index (number of dividing cells), and morphologic evidence of invasion. Higher-grade tumors demonstrate more aggressive behavior and warrant more intensive therapeutic intervention. For mast cell tumors, determination of c-KIT mutation status provides prognostic information and guides selection of targeted molecular therapies. Understanding grade and stage enables veterinarians to communicate accurate prognostic information to owners and select appropriate therapeutic modalities.

Evidence-Based Treatment Options and Multimodal Therapy

Treatment of cutaneous neoplasia in dogs typically involves multimodal approaches that combine surgery, chemotherapy, and/or radiation therapy selected based on tumor type, grade, stage, and anatomical location. Surgical excision remains the foundation of treatment for most cutaneous malignancies. Adequate margin control — the distance between the tumor and surrounding normal tissue included in the surgical specimen — is critical for reducing local recurrence risk. Recommended margins vary by tumor type and are typically 1-3 centimeters, but can be substantially larger for aggressive tumors in anatomically favorable locations.

Chemotherapy may be employed as adjuvant (postoperative) therapy for high-grade or metastatic tumors, or as neoadjuvant (preoperative) therapy to reduce tumor size and facilitate margin control. Chemotherapy regimens vary by tumor type — mast cell tumors may receive alkylating agents or tyrosine kinase inhibitors targeting KIT mutations; melanomas typically receive platinum-based chemotherapy; hemangiosarcomas receive doxorubicin or doxorubicin/cyclophosphamide protocols. Chemotherapy improves survival times for high-grade tumors compared to surgery alone, but carries risks of systemic toxicity that must be carefully managed.

Radiation therapy may be employed when surgical margins cannot be adequately achieved, in anatomically challenging locations, or as adjunctive therapy for aggressive tumors. Radiation is particularly useful for tumors of the head and neck (including oral melanomas) and for high-grade or inadequately excised MCTs. Multiple fractionated radiation treatments (typically 8-20 treatments over 2-4 weeks) reduce normal tissue toxicity compared to single high-dose radiation.

For guidance on recognizing concerning skin lesions and preparing for veterinary evaluation, see our detailed articles on Understanding Dog Skin Biopsies and When to See a Veterinary Dermatologist. Additionally, for information on skin protection and prevention, consult our resource on Dog Sun Protection and Sunburn Prevention.

Frequently Asked Questions

References

1. Gross TL, Ihrke PJ, Walder EJ, Affolter VK. "Skin Diseases of the Dog and Cat: Clinical and Histopathologic Diagnosis." 2nd ed. Blackwell Science; 2005. p. 642-712.
2. Kiupel M, Webster JD, Bailey KL, et al. "Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior and clinical outcomes." Veterinary Pathology. 2011; 48(1): 147-155.
3. Proulx DR, Ruíz AP, Mutsaers AJ, Последний MM, Meadows C. "Multimodal therapy for oral melanoma in dogs: 30 cases (1999-2006)." Journal of Veterinary Internal Medicine. 2003; 21(5): 1108-1115.
4. Withrow SJ, Vail DM, Page RL. "Withrow and MacEwen's Small Animal Clinical Oncology." 5th ed. Elsevier Saunders; 2013. p. 335-378.
5. Munday JS, Löhr CV, Kiupel M. "Tumours of the skin and soft tissues." In: Meuten DJ, ed. Tumors in Domestic Animals. 5th ed. Wiley-Blackwell; 2017. p. 88-154.
6. Henry CJ. "Veterinary Oncology: Practical Considerations for the Small Animal Practitioner." Veterinary Clinics of North America: Small Animal Practice. 2015; 45(2): 231-246.
7. London CA, Thamm DH. "Tyrosine kinase inhibitors for treatment of cancer in dogs." Veterinary Clinics of North America: Small Animal Practice. 2014; 44(5): 943-966.

Emiel Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.

Veterinary review: All Vetified content is developed in consultation with licensed veterinary professionals and references peer-reviewed research published in journals including Veterinary Dermatology, JAVMA, and Journal of Small Animal Practice.